Annette von Delft
M.D, Ph.D.
Head of Anti-Infectives, Centre for Medicines Discovery
Annette von Delft works on the discovery and development of novel small molecule inhibitors against viruses, bacteria and fungi. Her work covers projects from early target validation, target enablement, molecule discovery and preclinical development.
Annette's current focus is the preclinical development of a novel antivirals for pandemic preparedness, targeting coronaviruses, flaviviruses and enteroviruses, as part of the global consortia COVID Moonshot and ASAP (https://asapdiscovery.org/ ). On these projects, she works in close collaboration with Drugs for Neglected Disease initiative (DNDi).
Annette joined the BRC team in 2018 as a translational scientist with a focus on inflammation and immunity, and has initiated a range of early target validation projects in immunology, infectious disease and neuroscience.
Annette trained as a medical doctor at University of Leipzig (Germany) and received her D.Phil in Clinical Medicine at the University of Oxford in 2010, working on HCV T cell immunology and vaccine development under the supervision of Prof Eleanor Barnes. She then completed her medical foundation programme at Oxford University Hospitals.
Recent publications
-
Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals.
Journal article
Brun J. et al, (2025), Antiviral Res
-
Identification and characterization of human KALRN mRNA and Kalirin protein isoforms.
Journal article
Mould AW. et al, (2024), Cereb Cortex, 34
-
Enabling equitable and affordable access to novel therapeutics for pandemic preparedness and response via creative intellectual property agreements.
Journal article
Griffen EJ. et al, (2024), Wellcome Open Res, 9
-
An Update on SARS-CoV-2 Clinical Trial Results-What We Can Learn for the Next Pandemic.
Journal article
Arman BY. et al, (2023), Int J Mol Sci, 25
-
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.
Journal article
Boby ML. et al, (2023), Science, 382